In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

Jason M. Glover; Marc Loriaux; Jeffrey W. Tyner; Brian J. Druker; Bill H. Chang

doi:10.1002/pbc.23383

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

Jason M. Glover, Marc Loriaux, Jeffrey W. Tyner, Brian J. Druker, Bill H. Chang

Research output: Contribution to journal › Article › peer-review

21 Scopus citations

Abstract

Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.

Original language	English (US)
Pages (from-to)	576-579
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	59
Issue number	3
DOIs	https://doi.org/10.1002/pbc.23383
State	Published - Sep 2012

Keywords

ALL
Dasatinib
E2A-HLF

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.23383

Cite this

@article{2a288f1db25a498db4d52b134efc36ca,

title = "In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia",

abstract = "Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.",

keywords = "ALL, Dasatinib, E2A-HLF",

author = "Glover, {Jason M.} and Marc Loriaux and Tyner, {Jeffrey W.} and Druker, {Brian J.} and Chang, {Bill H.}",

year = "2012",

month = sep,

doi = "10.1002/pbc.23383",

language = "English (US)",

volume = "59",

pages = "576--579",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

AU - Glover, Jason M.

AU - Loriaux, Marc

AU - Tyner, Jeffrey W.

AU - Druker, Brian J.

AU - Chang, Bill H.

PY - 2012/9

Y1 - 2012/9

N2 - Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.

AB - Patients with t(17;19) acute lymphoblastic leukemia (ALL) have a dismal prognosis even with the most intensive current therapies that include stem cell transplant. We present the case of a patient with t(17;19)(q22;p13) gene rearranged B-cell precursor ALL whose lymphoblasts were found to have significant in vitro sensitivity to dasatinib. The patient tolerated the addition of dasatinib with combination therapy and remained in remission for over nine months until his recurrence. Therefore, future studies will be needed to interrogate whether dasatinib has any therapeutic benefit in children with t(17;19) B-cell precursor ALL.

KW - ALL

KW - Dasatinib

KW - E2A-HLF

UR - http://www.scopus.com/inward/record.url?scp=84863859105&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863859105&partnerID=8YFLogxK

U2 - 10.1002/pbc.23383

DO - 10.1002/pbc.23383

M3 - Article

C2 - 22038978

AN - SCOPUS:84863859105

SN - 1545-5009

VL - 59

SP - 576

EP - 579

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 3

ER -

In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this